Minerva Neurosciences (NASDAQ:NERV) Releases Earnings Results, Beats Estimates By $0.49 EPS

Minerva Neurosciences (NASDAQ:NERV) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.49, Zacks reports.

Minerva Neurosciences Stock Down 1.8 %

Shares of NASDAQ NERV traded down $0.03 during midday trading on Friday, hitting $1.67. The company had a trading volume of 18,703 shares, compared to its average volume of 47,113. Minerva Neurosciences has a twelve month low of $1.64 and a twelve month high of $3.69. The business has a 50-day simple moving average of $2.14 and a two-hundred day simple moving average of $2.38. The firm has a market capitalization of $11.68 million, a price-to-earnings ratio of -3.80 and a beta of 0.12.

Analysts Set New Price Targets

Several research analysts have issued reports on NERV shares. StockNews.com started coverage on shares of Minerva Neurosciences in a research report on Saturday, February 22nd. They set a “sell” rating on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a report on Wednesday.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.